Control of cell-cycle progression is achieved in part through the sequential activation and inactivation of cyclin-dependent kinases (CDKs). Each phase of the cell cycle has a characteristic pro®le of CDK activities, which is determined by the availability of the regulatory (cyclin) subunits, phosphorylations of the CDK subunits, and binding by CDK inhibitors (CDKIs) (Hengst and Reed, 1998) . The seven known mammalian CDKIs have been assigned to two families on the basis of sequence homologies and functional properties. The INK4 family members, p16   Ink4a   , p15   Ink4b   ,  p18 Ink4c and p19
Ink4d
, selectively bind and inhibit the cyclin D-activated G 1 kinases CDK4 and CDK6, whereas the members of the Cip/Kip family, p21
Cip1 , p27
Kip1 and p57 Kip2 , inhibit a broader range of cyclin/ CDK complexes . p27
Kip1 is generally expressed at high levels in quiescent cells, and constitutive overexpression of p27 Kip1 in cultured cells causes inhibition of cell proliferation and cell cycle arrest in G 1 . The activity of p27
Kip1 is up-regulated in vitro by a variety of extracellular antiproliferative signals, including transforming growth factor b, cell ± cell contact, growth factor or amino acid depletion, and agents such as cAMP and rapamycin Kato et al., 1994; Coats et al., 1996) , and can be down-regulated by interleukin 2 (Firpo et al., 1994) . Collectively, these ®ndings suggest a key role for p27 Kip1 in controlling pathways that connect mitogenic and anti-mitogenic signals to the cell cycle. A series of recent immunohistochemical studies have suggested that p27
Kip1 may be implicated as a tumor suppressor in human cancers. Over a wide range of tumor types, decreased expression of p27
Kip1 is a marker of disease progression and an adverse prognostic factor (Catzavelos et al., 1997; Porter et al., 1997; Loda et al., 1997) . However, while clearly supporting a role for p27
Kip1 in human cancer, the data from these studies are only correlative. To date, the only direct evidence that may identify loss of p27
Kip1 as a causal event in multistep tumorigenesis is the identi®cation of p27 Kip1 nonsense mutations in one case of breast cancer (Spirin et al., 1996) and one case of adult T-cell acute leukemia among more than 500 tumors examined for p27
Kip1 mutations (Spirin et al., 1996; Morosetti et al., 1995; Pietenpol et al., 1995; Kawamata et al., 1995; Ponce-CastanÄ eda et al., 1995) .
To investigate whether p27 Kip1 may be inactivated by epigenetic mechanisms in malignant melanoma, we examined a CpG island located in the 5' region of the p27 Kip1 gene for hypermethylation ( Figure 1 ). We ®rst analysed a region in exon 1 by methylation-speci®c PCR (MSP) (Herman et al., 1996) in a total of 61 uncultured melanomas, including 16 primary and 45 metastatic tumors. Positive signals for hypermethylation were observed in four of the metastatic tumors (9%) (Figure 1b) . To ensure that successful ampli®ca-tion was not a result of unspeci®c primer annealing or incomplete bisul®te conversion, all PCR products were subjected to direct sequencing. As shown in Figure 1c , all cytosines at CpG sites had remained as cytosine, whereas cytosines at non-CpG sites were converted to thymine. By contrast, sequence analysis of PCR products generated with primers speci®c for unmethylated p27
Kip1 alleles showed conversion of all cytosines (Figure 1c) . To examine the extent of methylation, two additional regions further upstream in the promoter were analysed using MSP (Figures 1a and 2 ). The four tumors displayed abnormal methylation in all three regions, while no evidence of p27 Kip1 methylation was found in normal cultured melanocytes (Figure 2 ).
Collectively, these data suggest that the entire 5' CpG island of p27 Kip1 is densely de novo methylated in a small fraction of melanomas.
Upon closer examination of the sequences of the bisul®te-PCR products generated with primers speci®c for methylated p27
Kip1 alleles, we discovered an A-to-G transition in one of the samples (FMB-55), which was not present in normal controls or in any of the other samples showing p27
Kip1 methylation ( Figure 3a , upper panel). This mutation is predicted to cause the substitution of histidine (CAT) with arginine (CGT) at residue 129 in the C-terminal half of p27 Kip1 , a region that is dispensable for kinase inhibitory activity. Only the mutant G-allele could be identi®ed by sequence analysis of the methylated alleles ( Figure  3a , upper panel), whereas only the normal A-allele was present in the bisul®te-PCR products generated with primers speci®c for unmethylated p27
Kip1 alleles ( Figure 3a , lower panel). The association between the codon 129 mutation and methylated CpG sites allowed us to use this mutation as a marker to investigate the transcriptional status of methylated p27
Kip1 alleles in the tumor. We initially sequenced a region encompassing codon 129 using genomic DNA from tumor FMB-55 as template, but could only identify the normal allele in the sequencing ladder (data not shown). Considering the sensitivity limit of sequence analysis, this suggests that the variant p27
Kip1 allele constitutes less than 20% of the total number of p27
Kip1 alleles in this tumor sample, and we therefore established a more sensitive allele-speci®c PCR assay that has the potential to detect less than 1% of a particular mutant allele or transcript in complex DNA or RNA populations. When using PCR primers speci®c for the normal A-allele, robust ampli®cation was achieved when using either genomic DNA or cDNA from the tumor as template (Figure 3b, upper panel) . In contrast, when using primers speci®c for the mutant G-allele, a positive PCR signal was obtained only from genomic DNA (Figure 3b , lower panel). These data suggest that methylation is associated with transcriptional silencing of the p27 Kip1 gene in situ. To further examine the patterns of p27
Kip1 methylation in melanoma, we extended our analyses by including a panel of 35 low-passage cell lines established from melanoma metastases. Three of the cell lines (FM9, FM60 and FM70) and single-cell clones generated from FM60 gave positive MSP signals for methylated p27
Kip1 alleles (Figure 4a) . Notably, FM60 and FM70 are derived from dierent metastases from the same patient and share a common clonal origin (Guldberg et al., 1997) , suggesting that p27 Kip1 methylation did not emerge as an in vitro artifact. Unexpectedly, all cell lines and single-cell clones with p27 Kip1 methylation also gave positive MSP signals for unmethylated p27
Kip1 alleles (Figure 4a ). Although these data suggest that only one of the p27
Kip1 alleles is methylated, we cannot formally exclude that the presence of both methylated and unmethylated p27 Kip1 alleles in the cell lines and single-cell clones could be due to dynamic changes of methylation during cell culture. Reverse-transcription PCR analysis showed expression of p27 Kip1 mRNA in the three cell lines with p27 Kip1 methylation, FM9, FM60 and FM70, and the single-cell clones of FM60, suggesting that transcription of p27
Kip1 was not fully silenced in any of these lines. Sequence analysis of the entire open reading frame and intron/exon borders of p27
Kip1 in the three cell lines demonstrated that methylation of one p27
Kip1 allele was associated with retention of the wild-type allele (data not shown).
Having shown that methylation of the p27 Kip1 5' CpG island correlates with loss of mRNA expression in situ (Figure 3) , it remained to be shown that the wild-type allele in cell lines with monoallelic p27
Kip1 methylation was not inactivated at the post-transcriptional level. To explore this, we examined abundance and subcellular localization of p27 Kip1 in cultured human diploid melanocytes and the melanoma cell lines, FM9, FM60, and FM70, using a combination of immunoblotting and immuno¯uorescence. The immunoblotting analyses of extracts prepared from exponentially growing cells revealed relatively low but clearly detectable levels of p27
Kip1 in the melanoma cell lines (see Figure 4b , for examples). Consistent with the immunoblotting data, immuno¯uorescence signals for p27 Kip1 were signi®cantly weaker in the three melanoma cell lines compared with normal melanocytes examined in parallel (Figure 4c,d) . Despite the reduced abundance of the protein, all cell types displayed similar localization of p27
Kip1 to cell nuclei, with variable reactivity also in the cytoplasm. The immunoblotting and immunostaining results were con®rmed with two independent antibodies against p27 Kip1 , and parallel examination of a control stable protein, CDK7 (Bartkova et al., 1996) , showed comparable abundance and localization in both the melanoma cell lines and normal melanocytes (see Figure 4b for examples). The Kip1 protein in the three melanoma cell lines supports the notion that one allele of the p27
Kip1 gene remains functional in these tumors. Collectively, our data (i) suggest that de novo methylation represents a novel mechanism for altering the expression levels of p27
Kip1 in human cells, (ii) directly implicate p27
Kip1 in the development and/or progression of malignant melanoma, and (iii) suggest that monoallelic silencing of p27
Kip1 may contribute to the malignant phenotype. In line with these ®ndings, Fero et al. (1998) proposed on the basis of mouse models that p27
Kip1 haploinsuciency may represent a causal event in multistep tumorigenesis. Upon exposure to g-irradiation or chemical carcinogens, mice with targeted disruption of one p27
Kip1 allele form tumors at a rate that is higher in p27
Kip1
-null mice and lower in normal animals (Fero et al., 1998) . Intriguingly, the tumors from p27
Kip1 heterozygous mice have retained the wild-type p27
Kip1 allele, suggesting that at least in this system p27 Kip1 does not conform to the classical criteria for a tumor suppressor. Functional data that may explain how p27
Kip1 and the other members of the Cip/Kip CDKI family can promote cell-cycle progression on a stoichiometric basis were recently reported by LaBaer et al. (1997) and Cheng et al. (1999) . At saturating concentrations, these molecules inhibit kinase activity, whereas at lower concentrations, they operate as cyclin-CDK assembly factors and thus promote cell cycling. Possibly, a twofold reduction in p27
Kip1 expression levels due to inactivation of one p27
Kip1 allele could be sucient to mediate a shift between the two functions and, accordingly, between inhibition and promotion of cell-cycle progression.
The patterns of p27 Kip1 expression in melanoma as evidenced by immunohistochemistry is highly heterogeneous (Flùrenes et al., 1998) . At least some forms of melanoma frequently display low staining for p27 Kip1 protein, suggesting that aberrant p27
Kip1 methylation is not the only mechanism causing reduced p27 Kip1 levels in melanoma. While allelotyping of the short arm of chromosome 12 and extensive mutation analyses have excluded abrogation of the p27
Kip1 gene itself as a major mechanism (Ponce-CastanÄ eda et al., 1995), a wide range of post-transcriptional mechanisms may be considered. For example, high proteolytic activity speci®cally directed against p27
Kip1 has been demonstrated in extracts prepared from colorectal and nonsmall cell lung cancers (Esposito et al., 1997; , suggesting that down-regulation of p27 Kip1 during tumorigenesis may occur at the post-transcriptional level through the ubiquitin-proteasome-mediated pathway (Pagano et al., 1995) . The molecular basis of this mechanism remains unknown.
In conclusion, we have demonstrated speci®c epigenetic aberrations of p27 Kip1 in a small but important fraction of malignant melanomas. Our data extend previous ®ndings in mouse models (Fero et al., 1998) that monoallelic inactivation of p27 Kip1 may confer a growth advantage to tumor cells, which would support a role for p27
Kip1 haploinsuciency in human cancers with frequent single allelic losses at 12p13, including leukemia (Pietenpol et al., 1995) , peritoneal mesothelioma (Decker et al., 1990) , ovarian cancer (Hatta et al., 1997) and non-small cell lung cancer .
